Healthcare - Biotechnology - NASDAQ - US
$ 1.84
-3.16 %
$ 138 M
Market Cap
-2.09
P/E
CASH FLOW STATEMENT
-21 M
OPERATING CASH FLOW
0
INVESTING CASH FLOW
0
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Context Therapeutics Inc.
| Net Income | -24 M |
| Depreciation & Amortization | 12 K |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 1.08 M |
| Change in Working Capital | 1.78 M |
| Others | 381 K |
| Free Cash Flow | -21 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | |
|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||
| Net Income | (24.0) | (14.8) | (10.5) | 6.6 | (6.4) |
| Depreciation & Amortization | 12 K | 9.27 K | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock Based Compensation | 1.1 | 1.0 | 0.5 | 0.2 | 0.8 |
| Other Operating Activities | 52 K | 0.6 | 3.4 | (9.2) | 2.2 |
| Change in Working Capital | 1.8 | (0.3) | (2.2) | 1.3 | 0.6 |
| Cash From Operations | (21.0) | (13.5) | (8.8) | (1.0) | (2.8) |
| INVESTING CASH FLOW | |||||
| Capital Expenditures | 0 | (0.5) | (0.2) | 0 | 0 |
| Other Items | 0 | 0 | 0 | 0 | 0 |
| Cash From Investing Activities | 0 | (0.5) | (0.2) | 0 | 0 |
| FINANCING CASH FLOW | |||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 0 | 0.1 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (0.1) | 5.0 | 1.0 | 2.0 |
| Cash From Financing Activities | 0 | (0.1) | 58.4 | 1.1 | 2.0 |
| CHANGE IN CASH | |||||
| Net Change In Cash | (21.0) | (14.2) | 49.3 | 0.1 | (0.9) |
| FREE CASH FLOW | |||||
| Free Cash Flow | (21.0) | (14.1) | (9.0) | (1.0) | (2.8) |